CPRX - Catalyst Pharmaceutical

-

$undefined

N/A

(N/A)

Catalyst Pharmaceutical NasdaqCM:CPRX Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Location: 355 Alhambra Circle, Coral Gables, FL, 33134, United States | Website: https://catalystpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.421B

Cash

580.7M

Avg Qtr Burn

N/A

Short % of Float

6.58%

Insider Ownership

6.28%

Institutional Own.

83.16%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
FIRDAPSE®(Amifampridine) Details
Lamber-Eaton myasthenic syndrome

Approved

Quarterly sales

AGAMREE® (Vamorolone) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

FIRDAPSE®(Amifampridine) Details
Autoimmune disease, Lamber-Eaton myasthenic syndrome

Approved

Quarterly sales

Approved

Quarterly sales

FIRDAPSE® (Amifampridine) Details
Autoimmune disease, Neuromuscular disease

Failed

Discontinued